The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study

Dual HER2-inhibition combined with neoadjuvant chemotherapy allows increased pathological complete response (pCR) rate. However, with the addition of new agents, there is a growing need to select patients to minimise overtreatment. Herein, we evaluated the 41-gene classifier TRAR to predict pCR to anti-HER2 therapies in the NeoALTTO trial.

Source: European Journal of Cancer - July 4, 2019 Category: Cancer & Oncology Authors: Serena Di Cosimo, Tiziana Triulzi, Sara Pizzamiglio, Loris De Cecco, Evandro de Azambuja, Debora Fumagalli, Lajos Putzai, Nadia Harbeck, Miguel Izquierdo, Lorena de la Pe ña, Maria Grazia Daidone, Jens Huober, Stefania Gori, Saverio Cinieri, Valter Torri Tags: Original Research Source Type: research